NCT02381470View on ClinicalTrials.gov

Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 11, 2019

Primary Completion Date

September 28, 2019

Study Completion Date

October 2, 2019

Conditions
Pulmonary Tuberculosis
Interventions
DRUG

Faropenem

Faropenem 600mg

DRUG

Amoxicillin/clavulanic acid

Amoxicillin 500mg/ clavulanic acid 125mg

DRUG

Cefadroxil

Cefadroxil 1g

DRUG

Rifampicin

Rifampicin 10mg/kg

Trial Locations (6)

Unknown

De La Salle Health Institute, Cavite

Tropical Disease Foundation, Makati City

Lung Center Philippines, Quezon City

National University Hospital, Singapore, Singapore

Infectious Diseases Institute, Kampala

Joint Clinical Research Centre, Kampala

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER

NCT02381470 - Trial of Faropenem and Cefadroxil (in Combination With Amoxicillin/Clavulanic Acid and Standard TB Drugs) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity and Effects on Novel Biomarkers | Biotech Hunter | Biotech Hunter